Skip to content

The validating of differential expression serum biomarkers in hepatitis B related acute on chronic liver failure with different prognosis

The validating of differential expression serum biomarkers in hepatitis B related acute on chronic liver failure with different prognosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024781
Enrollment
Unknown
Registered
2019-07-27
Start date
2019-07-25
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease

Interventions

Sponsors

Beijing YouAn Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18-65 years old, on the basis of chronic hepatitis B, short-term clinical syndrome of acute or subacute liver decompensation, as follows: (1) extremely weak, with obvious gastrointestinal symptoms; (2) jaundice rapidly deepens, serum TBil is greater than 10 times the upper limit of normal or daily increase >=17.1 umol/L; (3) bleeding tendency, PTA =1.5), and exclude other causes; (4) decompensated ascites; (5) with or without hepatic encephalopathy.

Exclusion criteria

Exclusion criteria: 1. patients with autoimmune diseases; 2. accompanied by other serious active physical and mental diseases, including uncontrolled primary kidney, heart, lung, vascular, neurological, digestive, metabolic diseases, immunodeficiency diseases or malignant tumors; 3. pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
anti-LFAA autoantibody;SPE, SEN, ACC;

Countries

China

Contacts

Public ContactLinlin Wei

Beijing YouAn Hospital, Capital Medical University

llmm0830@126.com+86 13811879216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026